93 related articles for article (PubMed ID: 16029648)
1. [Clinicopathology, clonality, and hormone production profile of prolactinoma].
Ma WB; Ikeda H; Yoshimoto T
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1382-7. PubMed ID: 16029648
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
3. Gender-related differences in prolactin secretion in pituitary prolactinomas.
Nishioka H; Haraoka J; Akada K; Azuma S
Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
[TBL] [Abstract][Full Text] [Related]
4. [The relationship between cell proliferation activity and secretory activity in pituitary adenoma--a review of 63 cases].
Asano K; Kubo O; Tajika Y; Huang MC; Takakura K
No To Shinkei; 1996 Jun; 48(6):543-9. PubMed ID: 8703557
[TBL] [Abstract][Full Text] [Related]
5. Comparative immunohistochemical analysis of estrogen receptor and chromogranin-A reactivity in plurihormonal human prolactinomas.
Talan-Hranilović J; Gnjidić Z; Sajko T; Vizner B; Vrkljan M
Acta Med Croatica; 2000; 54(2):59-63. PubMed ID: 11028110
[TBL] [Abstract][Full Text] [Related]
6. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas.
Rubinfeld H; Hadani M; Barkai G; Taylor JE; Culler MD; Shimon I
J Clin Endocrinol Metab; 2006 Jun; 91(6):2257-63. PubMed ID: 16595604
[TBL] [Abstract][Full Text] [Related]
7. Effect of vasoactive intestinal polypeptide (VIP) on growth hormone (GH) and prolactin (PRL) release and cell morphology in human pituitary adenoma cell cultures.
Fazekas I; Bácsy E; Varga I; Slowik F; Bálint K; Pásztor E; Czirják S; Gláz E
Folia Histochem Cytobiol; 2000; 38(3):119-27. PubMed ID: 10970071
[TBL] [Abstract][Full Text] [Related]
8. Volumes of pituitary adenomas related to hormone production, duration of symptoms and postoperative outcome.
Reinlie S; Haakonsen M; Eldevik OP; Nesbakken R
Acta Radiol Suppl; 1986; 369():306-9. PubMed ID: 2980482
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous prolactin transplantable tumor in the Wistar/Furth rat (SMtTW): a new animal model of human prolactinoma.
Trouillas J; Girod C; Claustrat B; Joly-Pharaboz MO; Chevallier P
Cancer Res; 1990 Jul; 50(13):4081-6. PubMed ID: 2354457
[TBL] [Abstract][Full Text] [Related]
10. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
11. Prolactin dynamics and tumour size in the prediction of surgical outcome for prolactinoma.
Gordon D; Richards A; Bulloch R; Cohen HN; Semple CG; Beastall GH; Thomson JA; Teasdale G
Q J Med; 1985 Feb; 54(214):141-51. PubMed ID: 3920723
[TBL] [Abstract][Full Text] [Related]
12. Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization.
Lloyd RV; Cano M; Chandler WF; Barkan AL; Horvath E; Kovacs K
Am J Pathol; 1989 Mar; 134(3):605-13. PubMed ID: 2466405
[TBL] [Abstract][Full Text] [Related]
13. Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma.
Lombardi M; Lupi I; Cosottini M; Rossi G; Manetti L; Raffaelli V; Sardella C; Martino E; Bogazzi F
Horm Metab Res; 2014 Dec; 46(13):939-42. PubMed ID: 25230324
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitory effects of melatonin on the development of 17-beta-estradiol induced prolactinoma in relation to plasma prolactin and peroxidative lipid contents].
Gao L; Xu JP; Shan HM; Zhang R; Xu RK
Sheng Li Xue Bao; 2001 Jun; 53(3):165-9. PubMed ID: 12589398
[TBL] [Abstract][Full Text] [Related]
15. Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas.
Chang CC; Chen FW; Hsieh HC
Taiwan Yi Xue Hui Za Zhi; 1989 May; 88(5):443-9. PubMed ID: 2507734
[TBL] [Abstract][Full Text] [Related]
16. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
17. Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Jones TH; Figueroa CD; Smith CM; Bhoola KD
Agents Actions Suppl; 1992; 38 ( Pt 2)():175-82. PubMed ID: 1462825
[TBL] [Abstract][Full Text] [Related]
18. Tumor volume improves preoperative differentiation of prolactinomas and nonfunctioning pituitary adenomas.
Wright K; Lee M; Escobar N; Pacione D; Young M; Fatterpekar G; Agrawal N
Endocrine; 2021 Oct; 74(1):138-145. PubMed ID: 33966173
[TBL] [Abstract][Full Text] [Related]
19. [Effect of calcium channel antagonist (nicardipine) on growth hormone and prolactin secretion in pituitary adenomas].
Kabuto M; Hayashi M; Kubota T; Kobayashi H; Nakagawa T; Katsumura H; Hosotani K
No To Shinkei; 1991 Jul; 43(7):637-43. PubMed ID: 1910948
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and inflammatory parameters in relation to baseline characterization and treatment outcome in patients with prolactinoma: insights from a retrospective cohort study at a single tertiary center.
Hofbauer S; Horka L; Seidenberg S; Da Mutten R; Regli L; Serra C; Beuschlein F; Erlic Z
Front Endocrinol (Lausanne); 2024; 15():1363939. PubMed ID: 38645431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
